ARCT · Arcturus Therapeutics Holdings Inc.
$10.99
+0.71 (+6.91%)
At close · Aug 20
Market Cap
$312.37M
Shares
28.42M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.99
Open$10.08
Day$10.06–11.47
52W close$5.53–23.16
Avg vol 30d756K
Short int7.2M · 25.4% float · 16.5d
Short vol61%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+49%
above
Price vs 50-day avg
+58%
above
RSI (14)
84
overbought
MACD trend
Positive
52-week position
31%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+90%
trailing
6-month return
+34%
trailing
YTD return
+79%
this year
Relative strength
+22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
25.36% of float · ▲ +2.9% MoM · 16.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
134 holders — mid 3-yr range
Squeeze score
100
high risk · 0–100
Fundamentals
Revenue growth
−46%
Y/Y
EPS growth
+20%
Y/Y
Free cash flow
$-74.5M
Balance sheet
$129.6M
net cash
Quant / Vol
risk profile
Volatility
88%
annualized · 1-yr
Max drawdown
−76%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+49%
Bullish
Price vs 50-day avg
+58%
Bullish
RSI (14)
84
Bearish
MACD trend
Positive
Bullish
52-week position
31%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
25.36% of float · ▲ +2.9% MoM · 16.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
134 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6
Now $11 · 31%
Range high $23
vs 200-day avg +49%
vs 50-day avg +58%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARCT
this stock
Arcturus Therapeutics Holdings Inc.
|
$312.37M | +79.3% | -46.1% | — | 25.4% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARCT | +39.8% | +89.8% | +33.5% | +90.8% | +79.3% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +41.8% | +86.5% | +22.4% | +88.7% | +67.5% |
Key facts
CIK
1768224
CUSIP
03969T109
13F (30d)
125 filings
125 filers
Visit website
Investor relations